nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—Haemoglobin—Mycophenolic acid—systemic scleroderma	0.00339	0.00339	CcSEcCtD
Fosamprenavir—Immune system disorder—Azathioprine—systemic scleroderma	0.00338	0.00338	CcSEcCtD
Fosamprenavir—Haemorrhage—Mycophenolic acid—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.00335	0.00335	CcSEcCtD
Fosamprenavir—Erythema multiforme—Leflunomide—systemic scleroderma	0.00334	0.00334	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Lisinopril—systemic scleroderma	0.00334	0.00334	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00333	0.00333	CcSEcCtD
Fosamprenavir—Myocardial infarction—Lisinopril—systemic scleroderma	0.00332	0.00332	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Fosamprenavir—Anorexia—Mometasone—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Fosamprenavir—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Fosamprenavir—Cardiac disorder—Leflunomide—systemic scleroderma	0.00328	0.00328	CcSEcCtD
Fosamprenavir—Immune system disorder—Leflunomide—systemic scleroderma	0.00319	0.00319	CcSEcCtD
Fosamprenavir—Myalgia—Captopril—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Fosamprenavir—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Fosamprenavir—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.00316	0.00316	CcSEcCtD
Fosamprenavir—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Fosamprenavir—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.00311	0.00311	CcSEcCtD
Fosamprenavir—Inflammation—Methotrexate—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Fosamprenavir—Malnutrition—Leflunomide—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Fosamprenavir—Flatulence—Leflunomide—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Fosamprenavir—Decreased appetite—Mometasone—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Lisinopril—systemic scleroderma	0.003	0.003	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.003	0.003	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Prednisone—systemic scleroderma	0.003	0.003	CcSEcCtD
Fosamprenavir—Fatigue—Mometasone—systemic scleroderma	0.00299	0.00299	CcSEcCtD
Fosamprenavir—Urethral disorder—Lisinopril—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Fosamprenavir—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Fosamprenavir—Malnutrition—Mycophenolic acid—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.00292	0.00292	CcSEcCtD
Fosamprenavir—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.00291	0.00291	CcSEcCtD
Fosamprenavir—Anorexia—Captopril—systemic scleroderma	0.0029	0.0029	CcSEcCtD
Fosamprenavir—Flatulence—Mycophenolic acid—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Fosamprenavir—Asthenia—Pentoxifylline—systemic scleroderma	0.00288	0.00288	CcSEcCtD
Fosamprenavir—Erythema multiforme—Lisinopril—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Fosamprenavir—Pruritus—Pentoxifylline—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Fosamprenavir—Angioedema—Leflunomide—systemic scleroderma	0.00281	0.00281	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00278	0.00278	CcSEcCtD
Fosamprenavir—Myalgia—Azathioprine—systemic scleroderma	0.00277	0.00277	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00276	0.00276	CcSEcCtD
Fosamprenavir—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00275	0.00275	CcSEcCtD
Fosamprenavir—Body temperature increased—Mometasone—systemic scleroderma	0.00274	0.00274	CcSEcCtD
Fosamprenavir—Abdominal pain—Mometasone—systemic scleroderma	0.00274	0.00274	CcSEcCtD
Fosamprenavir—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.00267	0.00267	CcSEcCtD
Fosamprenavir—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Fosamprenavir—Dizziness—Pentoxifylline—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Fosamprenavir—Decreased appetite—Captopril—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Fosamprenavir—Malnutrition—Lisinopril—systemic scleroderma	0.00264	0.00264	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00263	0.00263	CcSEcCtD
Fosamprenavir—Fatigue—Captopril—systemic scleroderma	0.00263	0.00263	CcSEcCtD
Fosamprenavir—Myalgia—Leflunomide—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Fosamprenavir—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Fosamprenavir—Flatulence—Lisinopril—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Fosamprenavir—Skin disorder—Azathioprine—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Fosamprenavir—Vomiting—Pentoxifylline—systemic scleroderma	0.00256	0.00256	CcSEcCtD
Fosamprenavir—Rash—Pentoxifylline—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Fosamprenavir—Dermatitis—Pentoxifylline—systemic scleroderma	0.00253	0.00253	CcSEcCtD
Fosamprenavir—Headache—Pentoxifylline—systemic scleroderma	0.00252	0.00252	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Methotrexate—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Fosamprenavir—Myalgia—Mycophenolic acid—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Captopril—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Fosamprenavir—Asthenia—Mometasone—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Fosamprenavir—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00247	0.00247	CcSEcCtD
Fosamprenavir—Nervous system disorder—Leflunomide—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Fosamprenavir—Pruritus—Mometasone—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Fosamprenavir—Skin disorder—Leflunomide—systemic scleroderma	0.00244	0.00244	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Fosamprenavir—Angioedema—Lisinopril—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Fosamprenavir—Body temperature increased—Captopril—systemic scleroderma	0.00241	0.00241	CcSEcCtD
Fosamprenavir—Abdominal pain—Captopril—systemic scleroderma	0.00241	0.00241	CcSEcCtD
Fosamprenavir—Anorexia—Leflunomide—systemic scleroderma	0.00239	0.00239	CcSEcCtD
Fosamprenavir—Nausea—Pentoxifylline—systemic scleroderma	0.00239	0.00239	CcSEcCtD
Fosamprenavir—Diarrhoea—Mometasone—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Fosamprenavir—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Fosamprenavir—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Fosamprenavir—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00232	0.00232	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.0023	0.0023	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.0023	0.0023	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Fosamprenavir—Anorexia—Mycophenolic acid—systemic scleroderma	0.00228	0.00228	CcSEcCtD
Fosamprenavir—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00228	0.00228	CcSEcCtD
Fosamprenavir—Myalgia—Lisinopril—systemic scleroderma	0.00225	0.00225	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Fosamprenavir—Vomiting—Mometasone—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Fosamprenavir—Rash—Mometasone—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Fosamprenavir—Asthenia—Captopril—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Fosamprenavir—Dermatitis—Mometasone—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Fosamprenavir—Decreased appetite—Leflunomide—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Fosamprenavir—Headache—Mometasone—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Fosamprenavir—Fatigue—Leflunomide—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Fosamprenavir—Pruritus—Captopril—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Fosamprenavir—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00212	0.00212	CcSEcCtD
Fosamprenavir—Neutropenia—Prednisone—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Fosamprenavir—Abdominal pain—Azathioprine—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Fosamprenavir—Body temperature increased—Azathioprine—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Fosamprenavir—Skin disorder—Lisinopril—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Fosamprenavir—Diarrhoea—Captopril—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Fosamprenavir—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00207	0.00207	CcSEcCtD
Fosamprenavir—Fatigue—Mycophenolic acid—systemic scleroderma	0.00207	0.00207	CcSEcCtD
Fosamprenavir—Nausea—Mometasone—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Fosamprenavir—Anorexia—Lisinopril—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Prednisone—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Fosamprenavir—Dizziness—Captopril—systemic scleroderma	0.00202	0.00202	CcSEcCtD
Fosamprenavir—Abdominal pain—Leflunomide—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Fosamprenavir—Body temperature increased—Leflunomide—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Prednisone—systemic scleroderma	0.00198	0.00198	CcSEcCtD
Fosamprenavir—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Fosamprenavir—Myocardial infarction—Prednisone—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Fosamprenavir—Hypersensitivity—Azathioprine—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Fosamprenavir—Vomiting—Captopril—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Fosamprenavir—Rash—Captopril—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Fosamprenavir—Dermatitis—Captopril—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Fosamprenavir—Headache—Captopril—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Fosamprenavir—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Fosamprenavir—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Fosamprenavir—Decreased appetite—Lisinopril—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Fosamprenavir—Fatigue—Lisinopril—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Fosamprenavir—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Fosamprenavir—Hypersensitivity—Leflunomide—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Fosamprenavir—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Fosamprenavir—Diarrhoea—Azathioprine—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Fosamprenavir—Haemoglobin—Prednisone—systemic scleroderma	0.00181	0.00181	CcSEcCtD
Fosamprenavir—Nausea—Captopril—systemic scleroderma	0.00181	0.00181	CcSEcCtD
Fosamprenavir—Haemorrhage—Prednisone—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Fosamprenavir—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Fosamprenavir—Asthenia—Leflunomide—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Fosamprenavir—Pruritus—Leflunomide—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Prednisone—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Fosamprenavir—Neutropenia—Methotrexate—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Fosamprenavir—Dizziness—Azathioprine—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Fosamprenavir—Asthenia—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Fosamprenavir—Diarrhoea—Leflunomide—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Fosamprenavir—Abdominal pain—Lisinopril—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Fosamprenavir—Body temperature increased—Lisinopril—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Fosamprenavir—Pruritus—Mycophenolic acid—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Fosamprenavir—Vomiting—Azathioprine—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Fosamprenavir—Rash—Azathioprine—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Fosamprenavir—Dermatitis—Azathioprine—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Fosamprenavir—Headache—Azathioprine—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Fosamprenavir—Dizziness—Leflunomide—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Fosamprenavir—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Fosamprenavir—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Fosamprenavir—Immune system disorder—Prednisone—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Fosamprenavir—Vomiting—Leflunomide—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Fosamprenavir—Hypersensitivity—Lisinopril—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Fosamprenavir—Dizziness—Mycophenolic acid—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Fosamprenavir—Rash—Leflunomide—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Fosamprenavir—Dermatitis—Leflunomide—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Fosamprenavir—Nausea—Azathioprine—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Fosamprenavir—Headache—Leflunomide—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Fosamprenavir—Malnutrition—Prednisone—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Fosamprenavir—Asthenia—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Fosamprenavir—Pruritus—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Fosamprenavir—Vomiting—Mycophenolic acid—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Fosamprenavir—Haemoglobin—Methotrexate—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Fosamprenavir—Rash—Mycophenolic acid—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Fosamprenavir—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Fosamprenavir—Haemorrhage—Methotrexate—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Fosamprenavir—Headache—Mycophenolic acid—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Fosamprenavir—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Fosamprenavir—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Fosamprenavir—Nausea—Leflunomide—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Fosamprenavir—Urethral disorder—Methotrexate—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Fosamprenavir—Diarrhoea—Lisinopril—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Fosamprenavir—Angioedema—Prednisone—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Fosamprenavir—Dizziness—Lisinopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Fosamprenavir—Erythema multiforme—Methotrexate—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Fosamprenavir—Nausea—Mycophenolic acid—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Fosamprenavir—Cardiac disorder—Methotrexate—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Fosamprenavir—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Fosamprenavir—Vomiting—Lisinopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Fosamprenavir—Immune system disorder—Methotrexate—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Fosamprenavir—Rash—Lisinopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Fosamprenavir—Dermatitis—Lisinopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Fosamprenavir—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Fosamprenavir—Headache—Lisinopril—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Fosamprenavir—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Fosamprenavir—Myalgia—Prednisone—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Fosamprenavir—Malnutrition—Methotrexate—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Fosamprenavir—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Fosamprenavir—Nausea—Lisinopril—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Fosamprenavir—Nervous system disorder—Prednisone—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Fosamprenavir—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Fosamprenavir—Skin disorder—Prednisone—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Fosamprenavir—Anorexia—Prednisone—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Fosamprenavir—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Fosamprenavir—Rash—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Fosamprenavir—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Fosamprenavir—Headache—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Fosamprenavir—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Fosamprenavir—Myalgia—Methotrexate—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Fosamprenavir—Decreased appetite—Prednisone—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Fosamprenavir—Fatigue—Prednisone—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Fosamprenavir—Nervous system disorder—Methotrexate—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Fosamprenavir—Skin disorder—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Fosamprenavir—Anorexia—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Fosamprenavir—Abdominal pain—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Fosamprenavir—Body temperature increased—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000976	0.000976	CcSEcCtD
Fosamprenavir—Hypersensitivity—Prednisone—systemic scleroderma	0.000944	0.000944	CcSEcCtD
Fosamprenavir—Decreased appetite—Methotrexate—systemic scleroderma	0.000931	0.000931	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000925	0.000925	CcSEcCtD
Fosamprenavir—Fatigue—Methotrexate—systemic scleroderma	0.000924	0.000924	CcSEcCtD
Fosamprenavir—Asthenia—Prednisone—systemic scleroderma	0.00092	0.00092	CcSEcCtD
Fosamprenavir—Pruritus—Prednisone—systemic scleroderma	0.000907	0.000907	CcSEcCtD
Fosamprenavir—Diarrhoea—Prednisone—systemic scleroderma	0.000877	0.000877	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000876	0.000876	CcSEcCtD
Fosamprenavir—Dizziness—Prednisone—systemic scleroderma	0.000848	0.000848	CcSEcCtD
Fosamprenavir—Abdominal pain—Methotrexate—systemic scleroderma	0.000847	0.000847	CcSEcCtD
Fosamprenavir—Body temperature increased—Methotrexate—systemic scleroderma	0.000847	0.000847	CcSEcCtD
Fosamprenavir—Vomiting—Prednisone—systemic scleroderma	0.000815	0.000815	CcSEcCtD
Fosamprenavir—Rash—Prednisone—systemic scleroderma	0.000808	0.000808	CcSEcCtD
Fosamprenavir—Dermatitis—Prednisone—systemic scleroderma	0.000807	0.000807	CcSEcCtD
Fosamprenavir—Headache—Prednisone—systemic scleroderma	0.000803	0.000803	CcSEcCtD
Fosamprenavir—Hypersensitivity—Methotrexate—systemic scleroderma	0.000789	0.000789	CcSEcCtD
Fosamprenavir—Asthenia—Methotrexate—systemic scleroderma	0.000769	0.000769	CcSEcCtD
Fosamprenavir—Nausea—Prednisone—systemic scleroderma	0.000761	0.000761	CcSEcCtD
Fosamprenavir—Pruritus—Methotrexate—systemic scleroderma	0.000758	0.000758	CcSEcCtD
Fosamprenavir—Diarrhoea—Methotrexate—systemic scleroderma	0.000733	0.000733	CcSEcCtD
Fosamprenavir—Dizziness—Methotrexate—systemic scleroderma	0.000708	0.000708	CcSEcCtD
Fosamprenavir—Vomiting—Methotrexate—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Fosamprenavir—Rash—Methotrexate—systemic scleroderma	0.000675	0.000675	CcSEcCtD
Fosamprenavir—Dermatitis—Methotrexate—systemic scleroderma	0.000675	0.000675	CcSEcCtD
Fosamprenavir—Headache—Methotrexate—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Fosamprenavir—Nausea—Methotrexate—systemic scleroderma	0.000636	0.000636	CcSEcCtD
